GRDN — Guardian Pharmacy Services, Inc.

Guardian Pharmacy Services, Inc. (GRDN) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $397.6 million, a 17% increase year-over-year, with 12% organic growth.
• Adjusted EBITDA: $39.5 million, up 53% year-over-year, with margins expanding to 9.9%.
• Gross Profit: Increased 27% to $85.5 million, with gross margins rising to 21.5%.
• Cash Balance: Grew to $66 million from $36 million in Q3 2025, reflecting strong cash conversion of approximately 60%.
• Full-Year 2025 Adjusted EBITDA: $115 million, exceeding guidance of $104 million to $106 million.

2. Strategic Updates and Business Highlights

• Organic Growth: Achieved 13% organic revenue growth driven by new resident additions and increased script volumes.
• Acquisitions: Completed three acquisitions in 2025, contributing to overall revenue growth of 18%.
• Clinical Initiatives: Over 100,000 clinical interventions conducted, benefiting 74,000 residents, and $56 million in cost savings achieved through insurance optimization.
• Vaccine Clinics: Administered over 120,000 vaccines in Q3 and Q4, with improved profitability from better purchasing and reimbursement.
• Technology Investments: Rolled out new secure messaging systems to enhance service reliability and operational efficiency.

3. Forward Guidance and Outlook

• 2026 Adjusted EBITDA Guidance: Raised to $120 million to $124 million, reflecting low double-digit growth expectations.
• Revenue Forecast: Maintained at $1.4 billion to $1.42 billion, anticipating impacts from the Inflation Reduction Act (IRA).
• Long-Term Growth: Acknowledged demographic trends favoring long-term care services, with an increasing number of residents requiring care.

4. Challenges and Points of Concern

• IRA Impact: Anticipated EBITDA impact from the IRA, introducing new operational complexities and pricing pressures.
• Competitive Pressures: Noted bankruptcy of a competitor in the long-term care pharmacy space, which could create market opportunities but also reflects industry instability.
• Integration Challenges: Acquisitions and greenfield startups continue to dampen overall margins by approximately 90 basis points.
• Market Dynamics: Ongoing consolidation in the long-term care pharmacy sector and potential cash flow constraints for peers could affect market conditions.

5. Notable Q&A Insights

• Durability of Vaccine Program: Improved profitability from the vaccine program is expected to continue into 2026.
• Contracting Strategy: Progress made in balancing profit contributions between generic and branded drugs, with ongoing efforts to align margins with prescription volume.
• M&A Pipeline: Robust pipeline for acquisitions remains, with a disciplined approach to potential opportunities arising from industry disruptions.
• Labor Efficiency: Increased efficiencies primarily driven by scaling existing operations rather than improvements in labor costs.

This summary encapsulates the key financial metrics, strategic initiatives, future outlook, and challenges faced by Guardian Pharmacy Services, Inc. during Q4 2025.